Business
Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update
Not even the release of a positive announcement has been able to stop the Recce Pharmaceuticals Ltd (ASX: RCE) share price from dropping today.
In afternoon trade, the biotechnology company’s shares are down 2.5% to 94 cents.
What did Recce announce?
This afternoon Recce Pharmaceuticals announced that the European Patent Office has granted patents relating to Recce 327 (R327) and Recce 529 (R529).
R327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria. This includes their superbug forms.
Whereas R529 is a new synthetic polymer formulation with indication against viruses. Recce is currently undertaking initial studies of R529 to indicate any potential therapeutic effect…
-
General18 hours agoMan refused bail charged with depicting Adolf Hitler and Nazi symbols on boat
-
Noosa News21 hours agoTributes for woman allegedly mowed down on footpath in Maroochydore; Guilherme Dal Bo charged
-
General14 hours agoTwo people arrested after man fatally shot at McLaren Flat
-
General12 hours agoWarner Bros Discovery board rejects rival $163bn bid from Paramount